Immune Efficacy Detection via T Cell Subgroup Quantification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for evaluating immune efficacy are limited, making it difficult to assess the immune system's state comprehensively and leading to variability in the effectiveness of immune cell therapy due to differences in individual immune efficacies.
Innovation Solution
A method involving the classification and quantification of T cell and natural killer cell subgroups based on antigen expression, with reference ranges derived from healthy populations, to determine immune efficacy and adjust lymphocyte levels for personalized therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current analytical indicators are used to evaluate immune efficacy, then the evaluation process is simple, but the assessment is incomplete and cannot present the immune system state comprehensively
Solution Approach 1:
The patent segments the immune system evaluation into multiple distinct components: T cell subgroup classification (naive, memory, regulatory, exhausted), natural killer cell classification (activated, inhibitory, cytotoxic), and functional activity assessment. This segmentation allows comprehensive evaluation of immune efficacy through multiple dimensions rather than a single indicator, resolving the contradiction between assessment completeness and method simplicity.
2Reliability
If cell amount selection in immune cell therapy is based on doctor's experience and cell types, then the treatment process is straightforward, but there is huge variability in effectiveness due to individual immune efficacy differences
Solution Approach 1:
The patent implements a feedback mechanism where pre-treatment immune efficacy assessment results directly inform post-treatment cell dosing decisions. The system measures baseline immune parameters, compares them against reference ranges, and uses this feedback to personalize the therapeutic cell amount for each patient, thereby improving treatment reliability while making the complexity manageable through systematic decision-making.
Solution Approach 2:
The patent changes the parameter basis for therapy dosing from generic cell type considerations to specific immune efficacy parameters (T cell subgroup percentages, natural killer cell activity levels). By adjusting dosing parameters based on measured immune status rather than fixed protocols, the system achieves more reliable and personalized treatment outcomes.
3Adaptability or versatility
If comprehensive immune efficacy detection is implemented, then personalized therapy can be achieved, but the detection method becomes more complex and time-consuming
Solution Approach 1:
The patent performs preliminary classification of T cells and natural killer cells into subgroups using standardized markers before functional assessment. This preliminary action organizes the complex detection into manageable stages, allowing parallel processing of multiple parameters and reducing overall detection time while maintaining comprehensive evaluation capability for personalized therapy.
Data Source
AI summary
In some embodiments of the present disclosure, a method for detecting immune efficacy is provided, including: generating quantity percentages of the plurality of T cell subgroups in the lymphocytes and quantity percentages of the nature killer cell subgroups in the lymphocytes to obtain actual percentages of the plurality of T cell subgroups and actual percentages of the nature killer cell subgroups; and judging whether immune efficacy is normal according to the actual percentages of the plurality of T cell subgroups and the actual percentages of the nature killer cell subgroups. Some embodiments of the present disclosure further provide a method of treating a cancer of an individual by regulating an actual number of a total number of T cells or nature killer cells.